← Human Trials & Peer-Reviewed Studies
Airway neural responses to kinins: tachyphylaxis and role of receptor subtypes.
Plain-language guide to PMID 9927354 (1999): double-blind randomized controlled trial of Kallidin.
Key Facts
- PMID
- 9927354
- Journal
- American journal of respiratory and critical care medicine
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Reynolds CJ et al. (3 authors)
- DOI
- 10.1164/ajrccm.159.2.9804132
What This Study Did, in Plain Language
What Was Tested
Researchers studied Kallidin in this randomized controlled trial publication.
To further define the role of neural responses in the hyperreactivity of inflamed human upper airways to bradykinin (BK), the researchers determined if repeated challenges with BK led to tachyphylaxis of neurally mediated responses in subjects with perennial allergic rhinitis.
The researchers also tested the hypothesis that enhanced reactivity to kinins in inflamed airways was caused by induction of B1-kinin receptors by comparing the effects of the selective B1-receptor agonist, des-Arg10-lysylbradykinin, and the B2 receptor agonist, BK, in the lower airways of asthmatics and in the upper airways of subjects with perennial allergic rhinitis.
Who Took Part
PubMed tags the participants as both men and women.
How the Study Was Run
The design is described as randomized, double-blind and crossover.
Because people in this Kallidin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Kallidin study, the assignments were hidden from both participants and investigators until the end.
In the crossover set-up each of the participants took both Kallidin and the comparison in turn, acting as their own control.
What Was Measured
The researchers also tested the hypothesis that enhanced reactivity to kinins in inflamed airways was caused by induction of B1-kinin receptors by comparing the effects of the selective B1-receptor agonist, des-Arg10-lysylbradykinin, and the B2 receptor agonist, BK, in the lower airways of asthmatics and in the upper airways of subjects with perennial allergic rhinitis.
The subject headings attached to it are Asthma, Bronchi, Bronchial Provocation Tests, Bronchoconstriction, Capillary Permeability, Inflammation and Kallidin.
What This Means in Plain Language
The paper is a randomized, double-blind and crossover study of Kallidin.
The publication is from 1999 (American journal of respiratory and critical care medicine), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.